Key result
Prostacyclin therapies, including intravenous epoprostenol and subcutaneous treprostinil, provide important treatment options for the management of pulmonary arterial hypertension.
This article provides a comprehensive review of the classification, pathophysiology, diagnostic algorithms, and therapeutic management of pulmonary arterial hypertension, highlighting advances in prostacyclin therapy.
Answers are grounded in this paper and cite their sources.
Prostacyclin therapies remain central to PAH care; this Level 5 review extends evidence synthesis while leaving optimal regimens open for prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Patricia L. Eells (2004) conducted a review in Pulmonary Arterial Hypertension. Prostacyclin Therapy was evaluated. Prostacyclin therapies, including intravenous epoprostenol and subcutaneous treprostinil, provide important treatment options for the management of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: